Mesentech

Developed novel chemistry that selectively delivers pharmaceuticals to a specific tissue

Company details
Company
Mesentech
Stage
Pre-seed

About

Mesentech

Mesentech has developed a bone-targeting prodrug MES1007 that avoids systemic exposure and side effects by specifically delivering drugs to the bone. Over the years, Mesentech founders have developed unique partnership with Merck, Cure Duchenne, and Charles H. Hood Foundation.

Our portfolio

Boutique Venture Partners backs authentic founders who transform industries and create new ones in healthcare and life sciences.